Market Place
Sourcing Support
Coya Therapeutics Updates Phase 1 Study of IL-2 + CTLA4-Ig in FTD
18 Dec 2024 //
BUSINESSWIRE
Coya Therapeutics to Join Chat at Evercore HealthCONx Conference
25 Nov 2024 //
BUSINESSWIRE
Coya Therapeutics CEO Dr. Arun Issues Letter to Stockholders
19 Nov 2024 //
BUSINESSWIRE
Coya Therapeutics Provides Q3 2024 Update & Financial Results
06 Nov 2024 //
BUSINESSWIRE
Coya Therapeutics Announces Arun Swaminathan as CEO
01 Nov 2024 //
BUSINESSWIRE
Coya reports positive response, safety in mid-stage Alzheimer`s drug trial
29 Oct 2024 //
REUTERS
Coya Therapeutics Closes $10M Private Placement
23 Oct 2024 //
BUSINESSWIRE
Coya Therapeutics Announces $10.0 Million Private Placement
22 Oct 2024 //
BUSINESSWIRE
Coya Therapeutics CEO Howard Berman Selected For PharmaVoice 100
08 Oct 2024 //
BUSINESSWIRE
Coya Therapeutics Joins Chardan`s Genetic Medicines Conference
24 Sep 2024 //
BUSINESSWIRE
Coya Therapeutics Reports COYA 302 Preclinical Data t of PD
16 Sep 2024 //
BUSINESSWIRE
Coya Therapeutics to Present at Upcoming Healthcare Conferences
03 Sep 2024 //
BUSINESSWIRE
Coya Therapeutics Promotes Arun Swaminathan To CEO Effective November 1st
19 Aug 2024 //
BUSINESSWIRE
Coya Therapeutics Reports Q2 2024 Results And Provides Corporate Update
12 Aug 2024 //
BUSINESSWIRE
Coya Therapeutics To Present Alzheimer`s Study Results At CTAD24
02 Aug 2024 //
BUSINESSWIRE
Coya Therapeutics Files New Patents For COYA 301 With GLP-1 Agonists
31 Jul 2024 //
BUSINESSWIRE
Coya Therapeutics Expands Research Collaboration For T Cell Exosome Platform
20 Jun 2024 //
BUSINESSWIRE
Coya Therapeutics Announces ALS Study Publication In Neurology
11 Jun 2024 //
BUSINESSWIRE
Coya`s Manuscript On Neurology Accepted In Frontiers In Neurology
03 Jun 2024 //
BUSINESSWIRE
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
28 May 2024 //
BUSINESSWIRE
Coya Completes Phase 2 Low Dose IL-2 Study In Alzheimer`s
22 May 2024 //
BUSINESSWIRE
Coya Therapeutics Announces $5M Strategic ADDF Investment
20 May 2024 //
BUSINESSWIRE
Coya Therapeutics Q1 2024 Unaudited Financials, Update
09 May 2024 //
BUSINESSWIRE
Coya Presents Updated ALS Biomarker Data
26 Apr 2024 //
BUSINESSWIRE
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
22 Apr 2024 //
BUSINESSWIRE
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
18 Apr 2024 //
BUSINESSWIRE
Coya`s Dr. Stanley Appel to Present ALS Biomarker Data at the Symposium
08 Apr 2024 //
BUSINESSWIRE
Coya Therapeutics Provides a Corporate Update & Reports Fiscal 2023 Results
19 Mar 2024 //
BUSINESSWIRE
Coya Therapeutics Presents ALS Biomarker Data at Conference
12 Mar 2024 //
BUSINESSWIRE
Coya Therapeutics to Participate in BTIG Fireside Discussion
12 Mar 2024 //
BUSINESSWIRE
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in FTD
06 Mar 2024 //
BUSINESSWIRE
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg)
29 Feb 2024 //
BUSINESSWIRE
Coya Therapeutics to Present Biomarker Survival Data in Large Cohort of ALS
22 Feb 2024 //
BUSINESSWIRE
Coya Issues Letter to Stockholders Highlighting Expansion of COYA 302
21 Feb 2024 //
BUSINESSWIRE
Coya Therapeutics Licenses Intellectual Property Rights
13 Feb 2024 //
BUSINESSWIRE
Coya Therapeutics to Participate in Chardan Biotech Leadership Call Series
18 Jan 2024 //
BUSINESSWIRE
Coya Therapeutics Announces Pipeline Expansion of COYA 302
16 Jan 2024 //
BUSINESSWIRE
Coya Announces Successful Pre-IND aMeetings to Advance COYA 302
05 Jan 2024 //
BUSINESSWIRE
Mr. Wilbur L. Ross Joins Board of Coya Therapeutics, Inc.
20 Dec 2023 //
BUSINESSWIRE
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
13 Dec 2023 //
BUSINESSWIRE
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
12 Dec 2023 //
BUSINESSWIRE
DRL partners with Coya Therapeutics to develop nerve disorder therapy
07 Dec 2023 //
BUSINESS-STANDARD
Coya Therapeutics Announces $26.5 Million Private Placement
06 Dec 2023 //
PRESS RELEASE
Coya and Dr. Reddy’s Enter into an Exclusive Collaboration
06 Dec 2023 //
BUSINESSWIRE
Coya Therapeutics Reports Q3 2023 Unaudited Financial Results
08 Nov 2023 //
BUSINESSWIRE
Coya Announces Acceptance of Presentation, Regulatory T Cell Expansion Strategy
27 Oct 2023 //
BUSINESSWIRE
Coya Announces Completion of Enrollment in Phase 2 Study of LD IL-2
09 Oct 2023 //
BUSINESSWIRE
Coya Presents Experimental Data Supporting the Mechanism of Action of COYA 302
05 Oct 2023 //
BUSINESSWIRE
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data
03 Oct 2023 //
BUSINESSWIRE
Coya Successfully Engineers Regulatory T Cell (Treg) with CTLA-4 Protein
07 Sep 2023 //
BUSINESSWIRE
Coya Announces Publication of Potential Novel Blood Biomarker Data in (ALS)
31 Aug 2023 //
BUSINESSWIRE
Coya To Present Novel Proof of Concept Exosome Modification Technology
25 Aug 2023 //
BUSINESSWIRE
Coya Therapeutics Reports Q2 2023 Unaudited Financial Results
08 Aug 2023 //
BUSINESSWIRE
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
03 Aug 2023 //
BUSINESSWIRE
Coya Announces the Appointment of Dr. Merit Cudkowicz as Clinical Advisor
19 Jul 2023 //
BUSINESSWIRE
Coya Therapeutics Appoints Dr. Fred Grossman, to President and CMO
05 Jul 2023 //
BUSINESSWIRE
Coya to Present Proof-of-Concept Clinical Data for Low-Dose Intl-2 (ld IL-2)
28 Jun 2023 //
BUSINESSWIRE
Coya Therapeutics Appoints Dr. Michelle Frazier as Senior Vice President
14 Jun 2023 //
BUSINESSWIRE
Coya deems dementia drug R&D plan `premature,` switches focus
12 Jun 2023 //
FIERCE BIOTECH
